Top Tweets for #ESMo25
I saved this slide from A. Gennari’s #ESMO25 presentation discussing the “6-month PFS ceiling” after CDK4/6 inhibition. Worth revisiting now that the full evERA results have been published.
evERA trial: Giredestrant plus everolimus after CDK4/6 inhibition in HR+/HER2− aBC
https://t.co/3mKdt2imEi
"Looks like between zongertinib and sevabertinib we got delivered twins at #ESMO25!" — @BalazsHalmosMD
New SOHO-01 video: two FDA approvals, the label numbers, and the 1L TKI debate.
@lexiuning @chulkimmd @stephenvliu @lungoncdoc @oncbrothers
@Bayer
https://t.co/k8xWMKJpvK
https://t.co/5J93ao2KoK
The always eloquent @AlbigesL @GustaveRoussy highlights key studies from #ESMO25 at #KCRS26 incl #NESCIO (@HaanenJohn), #KM-U03 (@crisuarez08), #OPTIC (@DrScottHaake @brian_rini @katy_beckermann) & more!
Quoting my #ESMO25 meta-analysis, the evidence continues to accumulate: gBRCA PV carriers are more likely to be resistant to CDK4/6is. This new retrospective study reached a similar conclusion👇
I believe current guidelines should include a cautionary note regarding the use of CDK4/6 inhibitors in gBRCA carriers.
https://t.co/mbgCLQhtpM
#ESMO25
Impact of gBRCA1/2 Mutations on CDK4/6i Efficacy in HR+/HER2– mBC
According to my meta-analysis, patients with gBRCA1/2 mutations have worse PFS and OS, underscoring the need to better understand this subgroup’s biology and develop more rational treatment approaches.
At #ASCO26 metastatic #breastcancer session, results from the PIK3CA-mt cohort of the VIKTORIA-1 trial
These data, combined with those presented at #ESMO25 on the PIK3CA wt cohort, show that gedatolisib combinations are effective in 2nd line regardless of PIK3CA status
@OncoAlert
JUST IN: @FDA approves datopotamab deruxtecan/TROP-2 ADC (Datroway, @DaiichiSankyo) for metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/L1 inhibitor.
Trial led by @RebeccaDSing & published @Annals_Oncology #ESMO25
https://t.co/JkYlKq0PET
@aprilchoi_md @TumorBoardTues @SunnieSKim @IntegrityCE @sundar_raghav @YJanjigianMD @KlempnerSam @FilippoPietran4 @GIMedOnc @AnwaarSaeed3 @rutikamehtaMD @ReetuMukherjiMD @NEJM Yes! In the follow up presentation at #esmo25, OS was stat significant. HR, 0.78; 95% confidence interval [CI], 0.6–0.96; p=0.021).
Take a look at this programme for some important highlights in oncogene-addicted #NSCLC data from #ESMO25 in this helpful overview of how emerging targeted therapies may shape practice.
From @herbloong and @lung_connect
Revisiting ESMO 2025: Highlights in oncogene-addicted NSCLC
Dr @herbloong joined us in Berlin at ESMO 2025 to share his perspective on new data
📺 He shares his highlights in this video
Endorsed by
@Exon20Group
@BiomarkerCo
@WarOnCancer
@LungCancerEu
@lcrf_org
@isliquidbiopsy
Supported by an Independent Educational Grant from Bayer.
🆕After the oral presentation at #ESMO25, the results of TROPION-Breast02 are now out in @Annals_Oncology @RebeccaDSing
Dato-DXd showed ⬆️PFS and ⬆️OS versus chemotherapy in 1st line for patients with advanced TNBC ineligible to immunotherapy
https://t.co/MON4pRu0Rw
I'm amazed by the progress of #bladdercancer research. I had to revise this paper after #ASCO25, #ESMO25, #GUASCO26. Thank you to @jclin@jclinicalinvestalinvest for their patience in trying to keep up with discovery. @tompowles1 @MattGalsky @AndreaNecchi @DrRosenbergMSK @UrogerliMD @MichvdHeijden
🔎 Revisiting #ESMO25: Highlights in oncogene-addicted #NSCLC
Dr @herbloong joined us in Berlin at #ESMO2025 to share his perspective on new data
📺 He shares his highlights in this video
Get the slides for more detailed insights: https://t.co/KPSeLwkbZF
🤝 Endorsed by @Exon20Group @BiomarkerCo @WarOnCancer @LungCancerEu @lcrf_org @isliquidbiopsy
Supported by an Independent Educational Grant from Bayer.
#MedEd #oncTwitter #MedTwitter #thoraciconcology #ESMO2025 #ESMO
@womenofteal LY4170156 features a topo-I payload; no ocular toxicity was reported at #ESMO25 (https://t.co/joBqBIrvkL).
While vision blurred was 4% (G1-2) here, it seems manageable given prior data.
Any added insights, Dr. @AinhoaMada? #ESGO2026
The latest #CancerScope features encouraging phase 3 data presented at #ESMO25 that show survival benefits with immunochemotherapy for patients with platinum-resistant ovarian cancer.
This marks a hopeful step forward for future treatments.
https://t.co/96fX7SkIck
@OncoAlert
Read in #CancerScope: Trial results presented at #ESMO25 and published in The New England Journal of Medicine show sacituzumab tirumotecan improved survival in advanced lung cancer.
Cancer Section Editor Dr. Daniel Morgensztern weighs in:
https://t.co/tJ5fpIPUgF
@OncoAlert
Now featured in CancerScope: Phase 3 data presented at #ESMO25 show 1st-line TROP2-targeted ADCs improve survival for patients with advanced triple-negative breast cancer.
Cancer Deputy & Section Editor @oreganruth provides clinical context:
https://t.co/GfKx5HoML1
@OncoAlert
Evidence is accumulating.
Consistent with our meta-analysis presented at #ESMO25, this retrospective cohort shows that first-line CDK4/6 + ET leads to shorter PFS in pathogenic BRCA1/2 and PALB2 carriers!
https://t.co/JDNkbdMXrd
#ESMO25
My meta-analysis on gBRCA1/2 & CDK4/6i in HR+/HER2– MBC
🔹 9 studies
🔹 gBRCA1/2 → shorter PFS & OS vs WT
🔹 Strongest effect in gBRCA2 (possible RB1 link?)
💬 gBRCA1/2 may indicate a negative prognostic profile under CDK4/6i therapy.
Predictive value??
Algorithm of ET ± targeted treatment options after ET + CDK4/6 inhibitors. Some options are not yet approved— caution!
From Dr. Alessandra Gennari’s excellent discussion at #ESMO25👇
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
118.9M followers
Cristiano Ronaldo
@cristiano
114.6M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90.1M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.3M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers